How can MSD improve its Keytruda immunotherapy to reduce side effects for cancer patients?

Introduction

Improving Keytruda's immunotherapy to reduce side effects for cancer patients is a critical challenge that could significantly enhance patient outcomes and quality of life. As we explore this product improvement opportunity, we'll focus on understanding the current landscape, identifying key pain points, and developing innovative solutions that align with MSD's broader objectives.

Step 1

Clarifying Questions (5 mins)

• Looking at the product context, I'm thinking about the specific cancer types Keytruda is currently approved for. Could you provide more information on the primary cancer types and stages where Keytruda is most commonly used?

Why it matters: This helps us focus our improvement efforts on the most impacted patient groups. Expected answer: Keytruda is primarily used for advanced melanoma, non-small cell lung cancer, and certain types of head and neck cancers. Impact on approach: We'd tailor our solutions to the specific needs and side effects experienced by these patient groups.

• Considering user behavior, I'm curious about the typical treatment regimen for Keytruda. Can you share details on the frequency of administration and the average duration of treatment?

Why it matters: Understanding the treatment pattern helps us identify opportunities to reduce cumulative side effects over time. Expected answer: Keytruda is typically administered every 3-6 weeks, with treatment lasting 6 months to 2 years or more. Impact on approach: We might explore ways to optimize dosing or develop complementary therapies to mitigate long-term side effects.

• Regarding pain points and market position, I'd like to understand how Keytruda's side effect profile compares to other immunotherapies. Do we have data on how our side effect rates compare to our main competitors?

Why it matters: This helps us benchmark our performance and identify areas where we can gain a competitive advantage. Expected answer: Keytruda has a similar overall side effect profile to other PD-1 inhibitors, but with slightly lower rates of severe immune-related adverse events. Impact on approach: We'd focus on further reducing immune-related side effects to maintain and extend our competitive edge.

• Considering company alignment, I'm interested in MSD's broader objectives for Keytruda. Are we primarily focused on expanding its use to new cancer types, or is improving the existing treatment experience a key priority?

Why it matters: This helps us align our improvement efforts with the company's strategic goals. Expected answer: While expanding to new indications is important, improving patient experience and outcomes in existing treatments is a top priority for MSD. Impact on approach: We'd prioritize solutions that can be implemented relatively quickly to benefit current patients while also considering long-term innovations.